PMID- 29600359
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20231213
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 1756
DP  - 2018
TI  - Target Therapy for Esophageal Adenocarcinoma.
PG  - 51-65
LID - 10.1007/978-1-4939-7734-5_5 [doi]
AB  - Adenocarcinoma of the esophagus is a deadly disease and median survival of 
      patients with metastatic disease is around 1 year only. There is an unmet need to 
      personalize treatment by identifying molecular targets and respective target 
      therapy in esophageal adenocarcinoma. There has been success in targeting the 
      human epidermal growth factor receptor 2 (HER2) and vasoendothelial growth factor 
      (VEGF) pathway while more failures were encountered in the clinical studies 
      targeting epidermal growth factor (EGFR), mammalian target of rapamycin (mTOR), 
      and mesenchymal-epithelial transition (MET). Studies using immune-checkpoint 
      inhibitors have shown early success, and we await mature data for clinical 
      application. In the chapter, the target therapy and novel treatment strategy will 
      be reviewed. In the future, it is hoped that advances in translational research 
      in targeted therapy against esophageal adenocarcinoma will bring about new 
      progress in clinical practice.
FAU - Lam, Ka-On
AU  - Lam KO
AD  - Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong 
      Kong, Queen Mary Hospital, Pokfulam, Hong Kong. lamkaon@hku.hk.
FAU - Kwong, Dora L W
AU  - Kwong DLW
AD  - Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong 
      Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Costimulatory and Inhibitory T-Cell Receptors)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (MET protein, human)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - P188ANX8CK (Trastuzumab)
RN  - Adenocarcinoma Of Esophagus
SB  - IM
MH  - Adenocarcinoma/blood/diagnostic imaging/*drug therapy/pathology
MH  - Antibodies, Monoclonal/pharmacology/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use
MH  - Biopsy
MH  - Blood Cell Count
MH  - Costimulatory and Inhibitory T-Cell Receptors/antagonists & inhibitors/metabolism
MH  - ErbB Receptors/antagonists & inhibitors/metabolism
MH  - Esophageal Neoplasms/blood/diagnostic imaging/*drug therapy/pathology
MH  - Esophagus/diagnostic imaging/pathology
MH  - Humans
MH  - Molecular Targeted Therapy/*methods
MH  - Proto-Oncogene Proteins c-met/antagonists & inhibitors/metabolism
MH  - Stroke Volume/drug effects
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/metabolism
MH  - Trastuzumab/pharmacology/therapeutic use
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors/metabolism
MH  - Ramucirumab
OTO - NOTNLM
OT  - Adenocarcinoma
OT  - Esophageal
OT  - Esophagogastric
OT  - Immunotherapy
OT  - Palliative
OT  - Target therapy
EDAT- 2018/03/31 06:00
MHDA- 2019/01/29 06:00
CRDT- 2018/03/31 06:00
PHST- 2018/03/31 06:00 [entrez]
PHST- 2018/03/31 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
AID - 10.1007/978-1-4939-7734-5_5 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2018;1756:51-65. doi: 10.1007/978-1-4939-7734-5_5.